Video

Dr. Bhalla on Sensitizing TNBC to PARP Inhibitors and Cisplatin

Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.

Kapil N. Bhalla, MD, chief of personalized cancer medicine at the University of Kansas Cancer Center in Kansas City, describes the findings from an in vitro study that examined treatment with histone deacetylase (HDAC) inhibitors in triple-negative breast cancer (TNBC) cells.

Treatment with pan-HDAC inhibitors such as vorinostat and panobinostat can induce Hsp90 hyperacetylation, which causes depletion in BRCA levels and other DNA response proteins. This treatment produces a DNA repair deficit within the TNBC cells while also causing DNA damage. This results in a treatment scenario that mimics what is observed with BRCA mutations.

Bhalla adds that inducing BRCAness from treatment with a HDAC inhibitor allows for effective combination strategies with PARP inhibitors or cisplatin. These combinations could result in a synergistic treatment approach in TNBC.

This study provides the rationale to test cisplatin, HDAC, and PARP inhibitor combination strategies in patients with TNBC with or without the presence of a BRCA1/2 mutation.

<<<

View coverage from the 2012 SABCS

Related Videos
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP
Deena Mary Atieh Graham, MD
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.